Purple Biotech Ltd. Sponsored ADR
PPBT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 110.2% and free cash flow fell 62.1%, each against the same quarter a year earlier.
Follow PPBT
Purple Biotech Ltd. Sponsored ADR (PPBT) Altman Z-score
Purple Biotech Ltd. Sponsored ADR's Altman Z-score for fiscal 2019 is −3.51, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2020 | 5.49 | 9.00 |
| FY2019 | −3.51 | 0.40 |
| FY2018 | −3.90 | (0.01) |
| FY2017 | −3.90 | — |
How fiscal 2019’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.32 | — | 0.39 | |
| Retained earnings / total assets | (3.36) | — | −4.71 | |
| EBIT / total assets | (0.49) | — | −1.60 | |
| Market value of equity / total liabilities | 3.92 | — | 2.35 | |
| Sales / total assets | 0.07 | — | 0.07 | |
| Altman Z-score | Distress zone | −3.51 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −9.16 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| PPBT Purple Biotech Ltd. Sponsored ADR | 5.5× |
| SILO Silo Pharma, Inc. compare | −3.1× |
| VRAX Virax Biolabs Group Limited compare | −5.3× |
| CLSDQ Clearside Biomedical, Inc. compare | −22.1× |
| TRVN Trevena, Inc. compare | −22.1× |
| OGEN Oragenics, Inc. compare | −67.3× |
| BRTX Biorestorative Therapies, Inc. compare | −71.0× |
| GNPX GENPREX compare | — |
| KAPA Kairos Pharma, Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets